Xanax XR Related Published Studies
Well-designed clinical trials related to Xanax XR (Alprazolam)
Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. [2007.05]
Current approaches to the pharmacologic treatment of anxiety disorders. [2007]
Different acute tolerance development to EEG, psychomotor performance and subjective assessment effects after two intermittent oral doses of alprazolam in healthy volunteers. [2007]
Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam. [2006.11]
The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle. [2006.10.01]
Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs. [2006.10]
Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers. [2006.09]
A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam. [2006.05]
A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. [2005.12]
Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. [2005.11]
A neurophysiological study of the detrimental effects of alprazolam on human action monitoring. [2005.10]
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. [2005.09]
Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer. [2005.08]
Effects of dehydroepiandrosterone and alprazolam on hypothalamic-pituitary responses to exercise. [2005.08]
A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam. [2005.06]
Sertraline and alprazolam in the treatment of panic desorder. [2005.05]
Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. [2005.05]
No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. [2005.04]
A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. [2005.02.01]
Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers. [2005]
Well-designed clinical trials possibly related to Xanax XR (Alprazolam)
[Effect of acupuncture combined with massage of sole on sleeping quality of the patient with insomnia] [2008.06]
Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. [2007.09]
Effectiveness of a meditation-based stress management program as an adjunct to pharmacotherapy in patients with anxiety disorder. [2007.02]
Connectivity analysis of EEG under drug therapy. [2007]
Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. [2006.11]
Modeling drug detection and diagnosis with the 'drug evaluation and classification program'. [2005.09]
Drug identification performance on the basis of observable signs and symptoms. [2005.09]
Effects of group experiential cognitive therapy for the treatment of panic disorder with agoraphobia. [2005.08]
Breast core-needle biopsy: clinical trial of relaxation technique versus medication versus no intervention for anxiety reduction. [2005.01]
Other research related to Xanax XR (Alprazolam)
Does oral alprazolam affect ventilation? A randomised, double-blind, placebo-controlled trial. [2008.06.18]
Protective effect of alprazolam against sleep deprivation-induced behavior alterations and oxidative damage in mice. [2008.04]
[Alprazolam use improves psychological status and reduces hospitalization costs in patients with paroxysmal supraventricular tachycardia underwent radiofrequency catheter ablation] [2007.10]
Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet. [2007.08]
Anxiolytic therapy with alprazolam increases muscle sympathetic activity in patients with panic disorders. [2007.07.31]
Alprazolam induced conformational change in hemoglobin. [2007.06.01]
Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition. [2007.05]
Protective effect of alprazolam in acute immobilization stress-induced certain behavioral and biochemical alterations in mice. [2007.05]
Combining alprazolam with systematic desensitization therapy for dental injection phobia. [2007.01.23]
Raman mapping of low-content API pharmaceutical formulations. I. Mapping of Alprazolam in Alprazolam/Xanax tablets. [2007.01]
Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. [2007]
Combining alprazolam with systematic desensitization therapy for dental injection phobia. [2007]
Alprazolam induced conformational change in hemoglobin. [2006.12.09]
Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam. [2006.08.30]
Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. [2006.06]
Alprazolam abuse in Texas, 1998-2004. [2006.02]
[The cognitive effect of alprazolam in healthy volunteers] [2006]
Topiramate use in alprazolam addiction. [2006]
Intra-ventral tegmental area heroin-induced place preferences in rats are potentiated by peripherally administered alprazolam. [2005.11]
Acute effects of alprazolam on risky decision making in humans. [2005.09]
Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects. [2005.04]
Alprazolam-related deaths in Palm Beach County. [2005.03]
Other possibly related research studies
Selegiline Transdermal System: An Examination of the Potential for CYP450-Dependent Pharmacokinetic Interactions With 3 Psychotropic Medications. [2007.02]
Seizure Incidence in Psychopharmacological Clinical Trials: An Analysis of Food and Drug Administration (FDA) Summary Basis of Approval Reports. [2007.01.12]
Drug-herb interactions: eliminating toxicity with hard drug design. [2006]
Disappointment of patients on antidepressant therapy after excimer laser treatment. [2006.10]
Oxcarbazepine use in essential tremor. [2006.10]
Clinical features and treatment outcome in Japanese patients with social anxiety disorder: chart review study. [2006.08]
Pregabalin: in the treatment of generalised anxiety disorder. [2006]
Quetiapine and citalopram: aetiological significances in serotonin syndrome. [2006.07.07]
Hypersensitivity to paroxetine. [2006.05]
[Acute psychosis and Behcet's disease: a case report] [2006.05]
Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4). [2006.07.03]
Enhanced sucrose pellet consumption induced by benzodiazepine-type drugs in squirrel monkeys: role of GABAA receptor subtypes. [2006.08]
Application of a computational decision model to examine acute drug effects on human risk taking. [2006.05]
The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. [2006.09]
Treatment of premenstrual disorders. [2006.04]
Types of medication errors in North Carolina nursing homes: a target for quality improvement. [2006.03]
The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. [2006.05]
Hyperforin in St. John's wort drug interactions. [2006.03]
Psychopathology of panic attacks in panic disorder. [2006.05]
Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. [2006.04]
Influence of personality disorder on the treatment of panic disorder--comparison study. [2005.12]
Anti-conflict effects of benzodiazepines in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA receptors. [2006.01]
Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. [2005.09]
Characterizations of long-term anxiolytic benzodiazepine prescriptions in veteran patients. [2005.12]
Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. [2006.06]
Postpartum depression without delivering a child? [2005.09]
Gateways to clinical trials. [2005.06]
Prescription pattern of benzodiazepines for inpatients at a tertiary care university hospital in Pakistan. [2005.06]
Effects of GABAergic modulators on food and cocaine self-administration in baboons. [2005.12.12]
Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. [2005.06.28]
Methadone-induced bradycardia. [2005.07]
Herb-drug interactions: a literature review. [2005]
Anxiolytic suppression of repetitive transcranial magnetic stimulation-induced anxiety in the rats. [2005.06]
One hundred seventy two deaths involving the use of oxycodone in Palm Beach County. [2005.01]
The vestibular dysfunction and anxiety disorder interface: a descriptive study with special reference to the elderly. [2005.05]
Estimation of transdermal permeation parameters in non-stationary diffusion experiments. Application to pre-treatment studies with terpenes. [2005.01]
Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed non-matching to position tests. [2005.04]
A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. [2005.02]
Twenty-four hour growth hormone secretion in patients with panic disorder. [2005.01]
Clinical and electromyographic characteristics of tremor in patients with generalized anxiety disorder. [2007.01]
Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? [2007.04]
Seizure Incidence in Psychopharmacological Clinical Trials: An Analysis of Food and Drug Administration (FDA) Summary Basis of Approval Reports. [2007.01.16]
Anxiolytic-like effect of 5-HT(2) ligands and benzodiazepines co-administration: comparison of two animal models of anxiety (the four-plate test and the elevated plus maze). [2007.02.27]
Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4). [2007.04]
Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. [2007.07]
Comparative effects of nonselective and subtype-selective gamma-aminobutyric acidA receptor positive modulators in the rat-conditioned emotional response test. [2007.05]
[Gabapentin treatment in a female patient with panic disorder and adverse effects under carbamazepine during benzodiazepine withdrawal] [2007.03]
Pharmacologic treatment of acute and chronic stress following trauma: 2006. [2006]
The treatment of depression in cancer patients: a systematic review. [2007.02]
Pregabalin: Its efficacy, safety and tolerability profile in generalized anxiety. [2007.09]
|
